What is the recommended treatment for an adult with right‑mid‑zone pneumonitis?

Treatment for Right Mid-Zone Pneumonitis in Adults

For an adult with right mid-zone pneumonitis (community-acquired pneumonia), initiate ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg daily immediately upon diagnosis if hospitalization is required, or prescribe amoxicillin 1 g orally three times daily for 5–7 days if the patient meets criteria for outpatient management. 1

---

Initial Assessment: Determining Site of Care

Use validated severity scoring (PSI or CURB-65) combined with clinical judgment to decide between inpatient and outpatient treatment. 1

Hospitalization Criteria

• Admit patients with PSI class IV–V or CURB-65 score ≥ 2. 1
• Hospitalize if any of the following are present: respiratory rate > 24 breaths/min, systolic blood pressure < 90 mmHg, oxygen saturation < 92% on room air, inability to maintain oral intake, altered mental status, or multilobar infiltrates. 2, 1
• Elderly patients (≥ 65 years) with relevant comorbidities (diabetes, heart failure, moderate-to-severe COPD, liver disease, renal disease, or malignancy) should have a lower threshold for admission. 2

ICU Admission Criteria

• Transfer to ICU if any one major criterion is met: septic shock requiring vasopressors OR respiratory failure requiring mechanical ventilation. 1, 3
• Alternatively, admit to ICU if ≥ 3 minor criteria are present: confusion, respiratory rate ≥ 30/min, systolic BP < 90 mmHg, multilobar infiltrates, or PaO₂/FiO₂ < 250. 1, 3

---

Outpatient Management (PSI I–III, CURB-65 0–1)

Previously Healthy Adults Without Comorbidities

• First-line: Amoxicillin 1 g orally three times daily for 5–7 days provides superior pneumococcal coverage, including many penicillin-resistant strains. 1, 4
• Alternative: Doxycycline 100 mg orally twice daily for 5–7 days covers both typical and atypical pathogens. 1, 4
• Macrolides (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should only be used in areas where pneumococcal macrolide resistance is documented < 25%. 1, 4 In most U.S. regions, resistance is 20–30%, making macrolide monotherapy unsafe as first-line therapy. 1

Adults With Comorbidities or Recent Antibiotic Use

• Combination therapy: Amoxicillin-clavulanate 875/125 mg orally twice daily PLUS azithromycin (500 mg day 1, then 250 mg daily) OR doxycycline 100 mg twice daily for 5–7 days. 1, 4
• Alternative monotherapy: Levofloxacin 750 mg orally once daily OR moxifloxacin 400 mg orally once daily for 5–7 days, reserved for β-lactam allergy or contraindications to macrolides. 1, 4

Outpatient Monitoring

• Clinical review at 48 hours (or sooner if symptoms worsen) to assess response, oral intake, and adherence. 2, 1
• Escalate to hospital if: no improvement by day 2–3, respiratory distress develops (RR > 30/min, SpO₂ < 92%), inability to tolerate oral antibiotics, or new complications such as pleural effusion. 2, 1
• If amoxicillin monotherapy fails, add or substitute a macrolide; if combination therapy fails, switch to a respiratory fluoroquinolone. 2, 1

---

Inpatient Management (Non-ICU)

Standard Empiric Regimen

• Ceftriaxone 1–2 g IV once daily PLUS azithromycin 500 mg IV or orally daily provides coverage for typical pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis) and atypical organisms (Mycoplasma, Chlamydophila, Legionella). 1, 4
• Alternative β-lactams: Cefotaxime 1–2 g IV every 8 hours OR ampicillin-sulbactam 3 g IV every 6 hours, always combined with azithromycin. 1
• Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily OR moxifloxacin 400 mg IV daily) is equally effective and reserved for penicillin-allergic patients. 1, 4

Critical Timing

• Administer the first antibiotic dose in the emergency department immediately upon diagnosis; delays beyond 8 hours increase 30-day mortality by 20–30%. 1, 4
• Obtain blood cultures and sputum Gram stain/culture before the first antibiotic dose to enable pathogen-directed therapy. 1, 4

Transition to Oral Therapy

• Switch from IV to oral antibiotics when the patient is hemodynamically stable (SBP ≥ 90 mmHg, HR ≤ 100 bpm), clinically improving, afebrile for 48–72 hours, respiratory rate ≤ 24 breaths/min, oxygen saturation ≥ 90% on room air, and able to take oral medication—typically by hospital day 2–3. 1, 4
• Oral step-down options: Amoxicillin 1 g three times daily PLUS azithromycin 500 mg daily (or azithromycin alone after 2–3 days of IV therapy). 1

---

ICU Management (Severe CAP)

Mandatory Combination Therapy

• Ceftriaxone 2 g IV once daily PLUS azithromycin 500 mg IV daily OR a respiratory fluoroquinolone (levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 1, 4, 3
• β-lactam monotherapy is inadequate for ICU patients and is associated with higher mortality. 1, 4
• For penicillin-allergic ICU patients: Aztreonam 2 g IV every 8 hours PLUS a respiratory fluoroquinolone. 1

Special Pathogen Coverage (Only When Risk Factors Present)

Pseudomonas aeruginosa

• Add antipseudomonal therapy only if: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization with IV antibiotics within 90 days, or prior respiratory isolation of P. aeruginosa. 1, 4
• Regimen: Piperacillin-tazobactam 4.5 g IV every 6 hours PLUS ciprofloxacin 400 mg IV every 8 hours OR levofloxacin 750 mg IV daily PLUS an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily). 1, 5

Methicillin-Resistant Staphylococcus aureus (MRSA)

• Add MRSA coverage only if: prior MRSA infection/colonization, recent hospitalization with IV antibiotics, post-influenza pneumonia, or cavitary infiltrates on imaging. 1, 4
• Regimen: Vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) OR linezolid 600 mg IV every 12 hours, added to the base regimen. 1, 4

---

Duration of Therapy

• Minimum treatment duration: 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 4
• Typical duration for uncomplicated CAP: 5–7 days. 1, 4
• Extended courses (14–21 days) are required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 2, 1

---

Monitoring and Reassessment

Inpatient Monitoring

• Monitor temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily. 2, 1
• If no clinical improvement by day 2–3: Obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications (pleural effusion, empyema, resistant organisms). 2, 1

Follow-Up

• Schedule clinical review at 6 weeks for all patients; obtain chest radiograph only if symptoms persist, physical signs remain abnormal, or the patient has high risk for underlying malignancy (smokers > 50 years). 2, 1

---

Common Pitfalls to Avoid

• Never use macrolide monotherapy in hospitalized patients—it fails to cover typical pathogens such as S. pneumoniae and leads to treatment failure. 1, 4
• Avoid macrolide monotherapy in outpatients when local pneumococcal macrolide resistance exceeds 25% (the situation in most U.S. regions). 1, 4
• Do not add broad-spectrum antipseudomonal or MRSA agents routinely—restrict to patients with documented risk factors to prevent resistance and adverse effects. 1, 4
• Do not delay antibiotic administration beyond 8 hours—this significantly increases mortality. 1, 4
• Obtain blood and sputum cultures before starting antibiotics in all hospitalized patients to allow pathogen-directed therapy and safe de-escalation. 1, 4